Abstract
The global increase in life expectancy has brought aging-related health challenges to the forefront, with coagulation disorders emerging as a significant cause of morbidity and mortality among the elderly. In Africa, the burden of coagulation abnormalities is becoming increasingly evident due to demographic shifts, the rising prevalence of noncommunicable diseases, and the persistent impact of infectious diseases that affect coagulation pathways. Despite this growing challenge, limited data and constrained healthcare resources hinder effective recognition and management of these conditions. Biomarkers such as D-dimer, prothrombin time, activated partial thromboplastin time, and platelet indices play a crucial role in diagnosing and monitoring coagulation disorders in elderly patients. However, the availability and utilization of these diagnostic tools remain inconsistent across African healthcare settings, limiting timely risk stratification and intervention. Emerging biomarkers offer potential for improved assessment.